ZEVRA DENMARK A/S – Trademark Portfolio
Entity Type: 65
ZEVRA DENMARK A/S holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include MYPLIFA, MIPLYFFA, and AMPLIFYASSIST. The owner is based in Frederiksberg.
Nordre Fasanvej 215
Frederiksberg 2000 , DK
Showing of trademarks Trademarks
Trademark Classifications
ZEVRA DENMARK A/S's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does ZEVRA DENMARK A/S have?
ZEVRA DENMARK A/S has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 6 abandoned.
What trademark classes does ZEVRA DENMARK A/S file in?
ZEVRA DENMARK A/S files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ZEVRA DENMARK A/S's most well-known trademarks?
ZEVRA DENMARK A/S's registered trademark portfolio includes well-known marks such as MYPLIFA, MIPLYFFA, and AMPLIFYASSIST. These are among 5 currently registered trademarks in the portfolio.
What is ZEVRA DENMARK A/S's trademark registration success rate?
ZEVRA DENMARK A/S has a 45% trademark registration rate, with 5 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.